The use of spironolactone in the diagnosis and the treatment of hypertension associated with mineralocorticoid excess.
D000236:Adenoma; D000307:Adrenal Gland Diseases; D000310:Adrenal Gland Neoplasms; D000450:Aldosterone / Q000378:metabolism; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002277:Carcinoma; D003900:Desoxycorticosterone / Q000378:metabolism; D005260:Female; D006801:Humans; D006929:Hyperaldosteronism / Q000150:complications / Q000188:drug therapy / Q000209:etiology; D006973:Hypertension / Q000145:classification / Q000188:drug therapy* / Q000209:etiology; D006977:Hypertension, Renal / Q000628:therapy; D007676:Kidney Failure, Chronic / Q000150:complications; D008901:Mineralocorticoids / Q000378:metabolism*; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000188:drug therapy; D012078:Renal Artery Obstruction / Q000150:complications; D012083:Renin / Q000097:blood; D013148:Spironolactone / Q000627:therapeutic use*
D000959:Antihypertensive Agents; D008901:Mineralocorticoids; D013148:Spironolactone; D003900:Desoxycorticosterone; D000450:Aldosterone; D012083:Renin